Does multimodality therapy improve clinical outcomes in patients with angiosarcoma of the scalp and face?
Multimodality therapy is associated with improved survival and locoregional control in angiosarcoma of the scalp and face, particularly in younger patients with resectable disease.
Multimodality therapy for angiosarcoma is associated with improved LRC, RFS, and OS. Younger patients with resectable disease undergoing multimodality therapy for angiosarcoma had the best clinical outcomes.
Patel et al. (Thu,) studied this question.